AchE Inhibitor and Insulin
| Status: | Completed |
|---|---|
| Conditions: | Diabetes |
| Therapuetic Areas: | Endocrinology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/1/2019 |
| Start Date: | April 19, 2017 |
| End Date: | December 14, 2018 |
Using Acetylcholinesterase Inhibitors to Promote Insulin Secretion in Human Beings
The investigator will examine the effect of a single dose of pyridostigmine, AchE inhibitor
on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose
tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and
insulin secretion response will be evaluated by measuring insulin and glucose at different
time points. The test will be carried out twice, once without and once with the
administration of a single dose of Pyridostigmine on two separate days. The investigator
hypothesizes that inhibiting AChE will potentiate insulin secretion.
on insulin secretion in healthy subjects. Each subject will undergo an intravenous glucose
tolerance test (IVGTT) where IV glucose will be administered and the glucose excursion and
insulin secretion response will be evaluated by measuring insulin and glucose at different
time points. The test will be carried out twice, once without and once with the
administration of a single dose of Pyridostigmine on two separate days. The investigator
hypothesizes that inhibiting AChE will potentiate insulin secretion.
Inclusion Criteria:
- 18 years and older
Exclusion Criteria:
- BMI >30 Kg/m2
- fasting glucose >100
- Glycohemoglobin (Hemoglobin A1C) 5.7% or more
- History of asthma
- Use of medications that may interfere with glucose metabolism
We found this trial at
1
site
Miami, Florida 33136
Principal Investigator: Maria del Pilar Solano, MD
Phone: 305-243-6145
Click here to add this to my saved trials
